Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines - PubMed (original) (raw)
. 1993 Oct 21;55(4):678-84.
doi: 10.1002/ijc.2910550428.
Affiliations
- PMID: 8406999
- DOI: 10.1002/ijc.2910550428
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines
R Brown et al. Int J Cancer. 1993.
Abstract
We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug cis-diamminedichloroplatinum (II), cisplatin. The majority of the independent cisplatin-resistant clones isolated by a single selection with cisplatin from the ovarian tumour cell line A2780 showed increased levels of p53 protein compared to the parental cell line. Elevated p53 protein levels were also observed in cisplatin-resistant ovarian human tumour lines isolated after multiple exposures to cisplatin (A2780/cp70 and OVIP/DDP). Direct PCR sequencing of p53 cDNAs showed that both the A2780/cp70 and the parental A2780 cell lines had a wild-type p53 gene sequence. The OVIP and OVIP/DDP lines both had a heterozygous mutation at codon 126. Cell-cycle analysis after gamma-irradiation or cisplatin treatment showed evidence of a G1/S and G2/M cell-cycle checkpoint in both A2780/cp70 and the sensitive parental cell lines. However, the resistant cell line A2780/cp70 showed less inhibition of DNA synthesis after gamma-irradiation than the sensitive cell line. Transfection of a mutant p53 gene construct (containing a mutation at codon 143, val to ala) into the A2780/cp70 resistant cells conferred a significantly increased sensitivity to cisplatin, suggesting that p53 is a direct determinant of cisplatin resistance in these cells. However, expression of this mutant p53 in the A2780 cells did not affect sensitivity.
Similar articles
- Prolonged wild-type p53 protein accumulation and cisplatin resistance.
Yazlovitskaya EM, DeHaan RD, Persons DL. Yazlovitskaya EM, et al. Biochem Biophys Res Commun. 2001 May 18;283(4):732-7. doi: 10.1006/bbrc.2001.4849. Biochem Biophys Res Commun. 2001. PMID: 11350044 - Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI. Pestell KE, et al. Int J Cancer. 1998 Sep 11;77(6):913-8. doi: 10.1002/(sici)1097-0215(19980911)77:6<913::aid-ijc19>3.0.co;2-1. Int J Cancer. 1998. PMID: 9714063 - Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E. Yu JJ, et al. Int J Oncol. 2000 Mar;16(3):555-60. doi: 10.3892/ijo.16.3.555. Int J Oncol. 2000. PMID: 10675489 - Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance.
Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR. Siddik ZH, et al. J Inorg Biochem. 1999 Oct;77(1-2):65-70. doi: 10.1016/s0162-0134(99)00144-0. J Inorg Biochem. 1999. PMID: 10626356 Review.
Cited by
- Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.
Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Tchounwou PB, et al. J Exp Pharmacol. 2021 Mar 18;13:303-328. doi: 10.2147/JEP.S267383. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33776489 Free PMC article. Review. - APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Yamazaki H, Shirakawa K, Matsumoto T, Kazuma Y, Matsui H, Horisawa Y, Stanford E, Sarca AD, Shirakawa R, Shindo K, Takaori-Kondo A. Yamazaki H, et al. PLoS One. 2020 Jan 8;15(1):e0223463. doi: 10.1371/journal.pone.0223463. eCollection 2020. PLoS One. 2020. PMID: 31914134 Free PMC article. - Targeting Ovarian Cancer Cell Cytotoxic Drug Resistance Phenotype with Xanthium strumarium L. Extract.
Francisco Fernandez M, Charfi C, Piloto-Ferrer J, Lidia González M, Lamy S, Annabi B. Francisco Fernandez M, et al. Evid Based Complement Alternat Med. 2019 Nov 15;2019:6073019. doi: 10.1155/2019/6073019. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31827554 Free PMC article. - IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis.
Lagunas-Cruz MDC, Valle-Mendiola A, Trejo-Huerta J, Rocha-Zavaleta L, Mora-García ML, Gutiérrez-Hoya A, Weiss-Steider B, Soto-Cruz I. Lagunas-Cruz MDC, et al. J Oncol. 2019 Sep 26;2019:7475295. doi: 10.1155/2019/7475295. eCollection 2019. J Oncol. 2019. PMID: 31662754 Free PMC article. - Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
Pan H, Wang F, Rankin GO, Rojanasakul Y, Tu Y, Chen YC. Pan H, et al. Int J Oncol. 2017 Nov;51(5):1508-1520. doi: 10.3892/ijo.2017.4145. Epub 2017 Oct 3. Int J Oncol. 2017. PMID: 29048667 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous